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Abstract
Background Biologics are now key drugs in the management of immune-mediated inflammatory diseases. However, the 
increasingly complex biologics environment and growing cost pressures in the UK have led to variability in drug commis-
sioning and inequity of patient access across regions.
Objectives Our objectives were to provide consensus recommendations for enhancing the current situation in biologic 
prescribing in the UK by balancing clinical freedom with equitable distribution of biologics given the limited availability 
of resources.
Methods A modified Delphi approach was used to reach integrated, cross-specialty consensus among dermatologists, rheu-
matologists and gastroenterologists practising within the English National Health Service (NHS).
Results We describe the concepts of clinical freedom and clinical judgement and demonstrate how, together with patient 
choice, they can be exercised in the context of biologic prescribing in the NHS. We highlight that in England, local varia-
tions occur that are at odds with National Institute for Health and Care Excellence (NICE) guidance; these variably limit 
the degree to which clinicians can exercise clinical freedom and impact on equity of patient access to treatments. We define 
factors encompassing a drug’s value and identify challenges to the measurement and interpretation of this concept, which 
can raise barriers to the freedom of clinical choice and appropriate prescribing decisions allowing practices of holistic and 
personalised medicine. Cross-specialty consensus recommendations on ensuring equitable access to biologics in the NHS 
while protecting appropriate and individualised drug selection for patients are provided. We have also provided strategies 
for improving physician–commissioner communication to harmonise equity of patient access to biologics across England 
and improve patient outcomes. Commentary from patient advisory groups indicates that they welcome our exploration that 
value does not equal cost and agree that there should be an emphasis on shared decision making, which requires the clinician 
to practice clinical freedom by aligning the patient’s needs and preferences with available treatment choices.
Conclusions This consensus highlights the need to strike a balance between clinical freedom and short-term cost restrictions 
to support equitable resource distribution within the English NHS. Consideration of these recommendations may help to 
harmonise local, regional and national services and balance equity of patient access to biologic treatments with excellence 
in the NHS.
Extended author information available on the last page of the article
Digital Features for this article can be found at https ://doi.
org/10.6084/m9.figsh are.13653 563
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    Key Points 
Clinical freedom and consideration of patient choice 
and preference are vital for individualised care. The 
increasing availability of new biologics and biosimilars 
adds cost-based complexity to prescribing decisions for 
patients who may require these drugs. Clinical freedom 
should be exercised within a value framework that forms 
the backbone of rigorous, transparent evidence reports to 
include available evidence and clinical experience.
Although UK National Institute for Health and Care 
Excellence (NICE) clinical guidance theoretically allows 
a degree of clinical freedom, local variations in interpre-
tation occur, with a resulting impact on equity of patient 
access to treatments. The clinical freedom within UK 
NICE clinical guidelines could therefore be harmonised 
across local services to ensure equity of patient access to 
treatments.
Communication and collaboration between clinicians 
and commissioners can foster optimal pathway develop-
ment for better value, access and patient outcomes.
1 Introduction
Biologics are a core part of treatment for many patients with 
moderate-to-severe immune-mediated inflammatory dis-
eases (IMIDs), such as psoriasis, psoriatic arthritis (PsA), 
rheumatoid arthritis (RA) and inflammatory bowel diseases 
(IBDs; Crohn’s disease and ulcerative colitis) [1–4]. These 
diseases have a number of commonalities in terms of patho-
physiological mechanisms, overlap in patient population and 
management strategies [5–8]. In addition to potential syner-
gies, this presents a number of shared challenges, of which, 
the balance between clinical freedom and equitable distribu-
tion of biologics is key.
Clinical practice guidelines increasingly acknowledge 
the benefits that biologics can offer patients [1, 9, 10]. Yet, 
although biologics demonstrate superior efficacy over con-
ventional therapies, particularly in patients with moderate-
to-severe IMIDs, they are notably more expensive. The 
recent availability of biosimilar agents for tumour necro-
sis factor inhibitors (TNFi) has relieved some aspects of 
cost pressures on healthcare systems [11–13]. However, 
biosimilar availability has coincided with the introduction of 
a number of biologics with novel modes of action, including 
inhibitors of interleukin (IL)-12/23, IL-23, IL-17 and anti-
integrins, which have different efficacy and safety profiles. 
In certain therapy areas, some of these novel biologics have 
demonstrated improved clinical outcomes versus TNFi in 
direct head-to-head clinical trials (see the Table in the elec-
tronic supplementary material [ESM]), meta-analyses and 
real-world observational studies in terms of short- and long-
term efficacy, durability, safety and longevity [9, 10, 14–31].
Clinical freedom, or a physician’s right and duty to do 
what they regard as the best for their individual patient, is 
a key concept in choosing treatments together with patients 
through shared decision making [32]. Interlinked with this 
concept is clinical judgement, or the physician’s ability to 
combine clinical experience and expertise with the best 
available evidence and resources to choose the appropriate 
treatment [33]. Both clinical freedom and clinical judgement 
are becoming increasingly important as the choice of avail-
able biologics continues to grow. The UK National Institute 
for Health and Care Excellence (NICE) guidelines are gen-
erally phrased to allow a degree of interpretation [34–37], 
which enables a physician to exercise some clinical freedom. 
Yet, within healthcare systems with finite resources, under-
standable onus is placed on decision makers to opt for the 
most cost-effective choice [11]. Emerging data show that this 
is translating into variations in biologic use across England 
due to local commissioning decisions and mandated clinical 
pathways [38]. There are likely multiple reasons behind this 
variability, including local expertise and historical patterns 
of use, which can leave patients subjected to an inequitable 
‘postcode lottery’ of available treatments [38].
Across the three specialty areas, local, regional and 
national harmonisation of commissioning and prescribing 
services is required to permit synergies in NICE guideline 
interpretation and ensure equity of patient access to biolog-
ics through shared decision making. The Delphi process, 
which is a structured, egalitarian method for incorporating 
multiple expert views, can help to establish and document 
recommendations in instances such as this in which evidence 
is lacking and issues are difficult to define [39–42]. In this 
report, we aimed to use a modified Delphi process to gener-
ate an integrated consensus on clinical freedom and equita-
ble use of biologics in England. We also offer practical strat-
egies to optimise patient access to biologics and to enhance 
existing guidance and excellence in clinical outcomes for 
patients with IMIDs by balancing treatment choice with 
value for the English National Health Service (NHS).
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2  Methodology
The panel consisted of invited representatives of special-
ties from across England, representing dermatology (n = 3), 
rheumatology (n = 2) and gastroenterology (n = 3).
A modified Delphi process was used to reach consen-
sus, consisting of an e-survey and a group meeting in Janu-
ary 2020. A literature review of 144 unique references was 
conducted to inform the e-survey content, using PubMed 
Central and the European, UK national and NICE clinical 
guidelines. Details of the search strategy and the full list of 
articles identified are presented in the ESM.
Consensus statements were voted on in the e-survey and 
using an anonymous mobile application during the meeting. 
E-surveys and meeting voting were programmed, admin-
istered and collated by OPEN Health Medical Communi-
cations to maintain blinded voting. Consensus statements 
assessed the level of agreement using the terms ‘strongly 
disagree’, ‘disagree’, ‘agree’ or ‘strongly agree’. Consen-
sus was defined as achievement of at least 75% ‘agree’ or 
‘strongly agree’. Results are reported as n/N voting ‘agree’ or 
‘strongly agree’ (e.g. 7/8 indicates seven of eight panellists 
voting ‘agree’ or ‘strongly agree’). Additional comments and 
discussions were recorded to supplement specific statements.
Following analysis of results and development of the 
manuscript, representatives from three UK patient advisory 
groups (National Rheumatoid Arthritis Society, Crohn’s & 
Colitis UK and the Psoriasis Association) were asked to 
comment on this manuscript and the relevance of its recom-
mendations for patients with IMIDs in England.
3  Results
3.1  Defining the Principle of Clinical Freedom 
and its Role in Clinical Choice
3.1.1  Expert Consensus
 (i) Clinical freedom enables a physician to select the 
best treatment option in partnership with each indi-
vidual patient (8/8 [100%]).
 (ii) Clinical freedom should be exercised within a value 
framework, utilising all available evidence (8/8 
[100%]).
Table 1  Factors that should be considered when deviating from a population pathway and that impact the choice of biologic prescription and 
influencing switching decisions, by consensus
Data are presented as n/N (%) unless otherwise indicated
AE adverse event
Factors To consider when deviating from a 
population pathway
Impacting choice of biologic pre-
scription and influencing switching 
decisions
Disease factors
 Disease severity 7/8 (87.5) –
 Disease phenotype and/or pattern of area affected 6/8 (75) 8/8 (100)
Patient factors
 Disease impact on the individual patient 8/8 (100) 8/8 (100)
 Response to previous treatments 7/8 (87.5) 8/8 (100)
 Previous AEs or family history thereof 6/8 (75) 8/8 (100)
 Comorbidities 8/8 (100) 8/8 (100)
 Patient’s age 6/8 (75) 6/8 (75)
 Patient’s race 6/8 (75) –
 Patient’s preferences and beliefs 8/8 (100) 8/8 (100)
 Patient’s adherence 7/8 (87.5) 8/8 (100)




 Efficacy 6/8 (75) 7/8 (87.5)
 Safety and tolerability profile 7/8 (87.5) 7/8 (87.5)
 Treatment convenience/acceptability 7/8 (87.5) 8/8 (100)
 Cost effectiveness of treatment – 7/8 (87.5)
 Value of treatment – 7/8 (87.5)
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 (iii) In the UK, factors affecting the degree to which clini-
cians can exercise clinical freedom include geograph-
ical location and disease specialty (8/8 [100%]).
 (iv) Clinical judgement involves the interpretation of 
all available sources of information to formulate a 
recommended management plan for a patient (8/8 
[100%]).
 (v) Clinical guidelines provide a useful framework for 
how treatment options may be used at a population 
level. However, when determining an individualised 
treatment plan, the exercise of clinical judgement 
remains vital (8/8 [100%]).
• The panel reached consensus on factors that should 
be considered when deviating from a population path-
way, which are summarised in Table 1.
 (vi) In order to optimise care for both individual patients 
and the larger population, it is important for clinical 
guidelines and commissioning groups to strike a bal-
ance between clinical freedom and restrictions that 
support equitable resource distribution (8/8 [100%]).
3.1.2  Additional Comments
Debate on the exercising of clinical freedom and healthcare 
system resourcing practices is ongoing. Clinical judgement 
and clinical freedom are interlinked with patient choice and 
preference, and all play a role in appropriate prescribing 
for individual patients in a given value framework. Value 
frameworks, such as that devised by the Institute for Clini-
cal and Economic Review, aim to provide sustainable access 
to high-value care for all patients. They offer a conceptual 
framework to assess an intervention’s long-term value for 
money through its incremental cost effectiveness—including 
additional benefits, disbenefits and potential cost offsets for 
new treatments over a patient’s lifetime—to inform decisions 
both at the patient/physician level and at the population level 
[43–45]. Clinical practice decisions are based on available 
evidence and experience; individual patients require tailored 
treatment according to the physician’s judgement, and deci-
sions should only be made after discussion with the patient 
[32]. Indeed, many clinicians argue that primary focus on 
the individual patient is the basis of clinical freedom [46], 
meaning that clinical freedom is a significant facilitator to 
the practice of personalised care. Table 1, which shows fac-
tors to consider when deviating from a population pathway, 
could be construed as suggesting that cost is not a considera-
tion. Rather, it is intended that cost should not be the sole 
consideration, unless all other factors listed are equal.
In the specific case of the English healthcare system, a 
balance between clinical freedom and equitable resource 
distribution would continue to ensure fair implementation 
of NICE guidance.
3.2  The Value of Biologics
3.2.1  Expert Consensus
 (i) Interpretation of drug value is hampered by a lack 
of available evidence relating to long-term impact 
across a range of outcome measures of importance 
to patients, the healthcare system and society (8/8 
[100%]).
• The panel reached consensus on factors that are 
encompassed by a drug’s value, which are shown in 
Table 2.
 (ii) Lack of transparency on drug pricing, regional vari-
ations, cost fluctuations and complex contracting 
arrangements present additional challenges to phy-
sicians’ abilities to assess value (8/8 [100%]).
3.2.2  Additional Comments
The term ‘drug value’ can often be misunderstood or 
improperly used. This may present a challenge to the free-
dom of clinical choice and appropriate prescribing decisions 
that allow the practice of holistic and personalised medicine.
Efficacy was agreed to be a factor encompassed by a 
drug’s value and that should impact choice of biologic pre-
scription or the decision to switch between agents. How-
ever, efficacy is a composite of several aspects, including 
short- and long-term clinical scores (e.g. Psoriasis Area 
and Severity Index response, American College of Rheu-
matology response, Crohn’s Disease Activity Index), speed 
of response, durability and patient-reported outcome meas-
ures. Clinical trial data suggest that novel biologics appear 
to offer additional value for particular patients over older 
agents or conventional non-biologics. The evidence base for 
drug impact across a range of clinical outcomes is limited 
but growing. For example, there is now evidence showing 
reductions in the incidence of cardiovascular disease in 
patients receiving adalimumab for RA [47], whilst there is 
increasing evidence and guidance to state that some TNFi 
Table 2  Factors encompassed in the concept of a drug’s value, by 
consensus
Data are presented as n/N [%] unless otherwise indicated
Factors encompassed in the concept of a drug’s value
 Quality (6/8 [75])
 Efficacy (8/8 [100])




 Potential to offset other healthcare costs (8/8 [100])
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(adalimumab, certolizumab pegol, golimumab, infliximab) 
may be possible treatment options during pregnancy in cer-
tain patients for whom the benefit of staying on treatment 
outweighs any potential risk to the foetus [9, 10, 48–53]. 
Yet, most registration study data are short term in nature, 
typically demonstrating outcomes of no longer than 1 year 
and with primary focus on clinical scores [35, 54–71]. This 
highlights the continued lack of published evidence to dem-
onstrate a drug’s value.
It has been argued that clinical freedom may be limited 
by proscriptive treatment and resourcing mandates or reim-
bursement practices [72]. However, the authors argue that 
a lack of evidence to demonstrate value can also be a limit-
ing factor. In the absence of unlimited resources, medical 
care must be restricted to interventions of proven value. 
Therefore, some suggest that, without evidence of efficacy 
and safety, resources should not be allocated to a particular 
treatment [73–75]. Although biologics have revolutionised 
the management of many IMIDs, there remains interpatient 
variability in clinical and safety responses to therapies [76], 
and some published literature from randomised controlled 
trials (RCTs) is not always applicable to a certain patient’s 
situation. Therefore, the clinician’s experience should be 
included among available evidence to be used within the 
value framework, enabling them to choose from multiple 
agents or classes of agents, and to optimise outcomes for 
each patient.
3.3  Equitable Use of Biologics in the English 
Healthcare System
3.3.1  Expert Consensus
 (i) Clinical freedom to prescribe across all available 
treatment modalities is important to offer personal-
ised care to patients (8/8 [100%]).
• Consensus was reached on a number of factors that 
can impact choice of biologic prescription and influ-
ence the decision to switch from one biologic class to 
another (Table 1).
 (ii) Local pathways can help commissioners and clini-
cians reach a shared understanding of how national 
guidelines may impact upon their patient popula-
tions. However, variable interpretations and setting 
of additional barriers and targets create inequity of 
patient access (8/8 [100%]).
 (iii) Effective development, implementation and updat-
ing of current pathways requires close cooperation 
between clinicians and local commissioners. It is 
vital that these two groups maintain ongoing, open 
and transparent dialogue (8/8 [100%]).
3.3.2  Additional Comments
The availability of newer biologic options has expanded 
therapeutic options for patients with IMIDs; however, it 
should be noted that their availability in IBD has so far 
been slower than in psoriasis and PsA, which is mirrored by 
a slower rate of change in NICE guidelines and treatment 
choice availability for biologic-eligible patients in clinical 
practice.
In psoriasis and PsA, novel biologics may be consid-
ered over TNFi, especially for patients with specific disease 
characteristics such as those with a more aggressive disease 
course, involvement of vulnerable areas (e.g. genitals), a 
worse phenotype, or other comorbidities, all of which may 
increase impact on quality of life [1, 9]. In addition to poten-
tial improvements in efficacy, access to drugs with better 
safety profiles is particularly important for certain patient 
subgroups [9, 10, 20, 23, 77]. Clinicians may have a choice 
of biologic classes and will therefore need to consider vari-
ations in a patient’s disease presentation, disease severity 
and comorbidities when deciding which drug to use. For 
example, in patients presenting with multiple IMIDs, it may 
be logical to select an agent that is effective across disease 
areas and that would not otherwise be first choice. TNFi 
biosimilars have an important role in clinical practice by 
reducing direct drug costs. However, as with any biologic, 
biosimilar use must be exercised within a framework that 
considers clinical value as far as evidence is available. 
This includes the growing literature base assessing factors 
beyond direct costs such as tolerability issues (e.g. injection 
site reactions with citrate-containing agents), efficacy (e.g. 
the nocebo effect) and indirect costs (e.g. the administra-
tive costs or increased healthcare utilisation associated with 
non-medical switching) [78–85]. Of note, although these 
recommendations were made with a specific focus on bio-
logics, the concept can be extrapolated to other drugs with a 
high unit cost, e.g. targeted systemic small molecule inhibi-
tors such as Janus kinase (JAK) and phosphodiesterase E4 
(PDE4) inhibitors.
3.4  Practical Strategies to Optimise Patient Access
3.4.1  Improving Dialogue
Enhanced communication between clinician and commis-
sioner is critical to improve equity of access that aligns 
with the principles of NICE guidelines and permits clinical 
freedom. Commissioners should understand the common-
alities and differences between IMIDs. Although recom-
mendations for one may not necessarily transfer to others, 
there are significant overlaps in the specialties. Similarly, 
understanding the pricing factors involved in commissioning 
decisions would aid physicians in assessing a drug’s value, 
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which cannot be complete without knowledge of cost. Some 
clinical commissioning groups (CCGs) or clinician pathway 
groups use tables that group biologics by cost bands to aid 
decision making. These may be beneficial if implemented 
more widely across England.
Clinicians are best placed to shift the focus from 
resources and costs to health outcomes, quality of life and 
patient satisfaction. Hence, medical participation in manage-
ment, as well as perhaps commissioning decisions around it, 
is imperative [74]. Understanding decision making by clini-
cians helps clinical leaders and policy makers to determine 
resource allocation, which then allows clinicians to make 
appropriate treatment selections [86].
A good relationship between commissioners and clini-
cians is key to good communication; conversely, the lack of 
such a relationship can present challenges to current prac-
tices. Strategies for improving communication could help 
resolve the majority of disagreements around commission-
ing decisions (see Box 1). In rare circumstances, it may be 
necessary to consider formal proceedings such as a letter to 
the medical director outlining the grounds of concern and 
invoking the formal complaint process. In this instance, we 
regard it as good practice to copy the patient into corre-
spondence so they can be fully aware of ongoing discussions 
regarding their care.
Box 1  Methods for improving physician–commissioner communica-
tion
Regular informal meetings, emails or phone calls between commis-
sioners and clinicians to facilitate open, ongoing communication 
and reduce the overall burden at official commissioning meetings.
Physician attendance at relevant commissioning meetings, particu-
larly with presentation of case studies, highlighting patient impact 
to illustrate why pathways need to be adapted or developed.
Patient focus groups to help practitioners and commissioners under-
stand patient perspective.
Patient organisations can help with focus groups by recruiting 
patients with different characteristics.
Agreements to share cost savings (note that this will rely on trans-
parent drug costings).
Investment by commissioners in clinical services or projects that 
improve efficiency or allow savings (e.g. funding posts that facili-
tate switching to biosimilars).
Consideration of management strategies beyond biologics.
 
3.4.2  Aligning Clinical Judgment and Commissioning 
Decisions
Ideally, collaboration between physicians and commis-
sioning groups should foster the development of suitable 
pathways and protocols that reflect the clinical freedom 
permitted by NICE guidelines, which not only respect the 
physician’s ability to select management strategies for indi-
vidual patients but also eliminate geographical variations 
in care. Improved dialogue between specialties would addi-
tionally benefit pathway development due to differences in 
clinical outcomes: the effectiveness of a specific biologic 
in one disease may be suboptimal in another, knowledge 
of which can be improved through interactive working and 
cross-specialty dialogue.
In some cases, it may be necessary to challenge a com-
missioning decision, such as where the clinician believes 
a particular CCG pathway mandates limits and targets for 
certain agents to the detriment of a patient. Improved com-
munication and informal discussion between clinicians and 
commissioners should be the first port of call to reach a solu-
tion or compromise. Figure 1 depicts a process and resource 
bank that aims to support physicians and patients to resolve 
a misalignment between clinical judgement, as per NICE 
guidelines and a CCG pathway.
Independent/individual funding requests (IFRs) may also 
be a route to funding of a drug that is not supported in a 
CCG pathway or by the English NHS. They are submitted 
when the clinician believes that an individual patient has 
an ‘exceptional health need’ and are considered by a panel 
of clinicians, health experts and laypeople on the basis of 
evidence for clinical and cost effectiveness, as well as equity 
for the whole population [87, 88]. IFRs are not appropriate 
where a drug is NICE approved and when proposed use is 
within the relevant NICE technology appraisal guidance. 
The authors express variable sentiments towards IFRs, 
which is likely reflective of local CCG variations. Some 
feel that they are not a pragmatic way to reach a solution, 
due to the demand for specific, robust outcome and eco-
nomic evidence, despite the fact that the patient’s case is 
exceptional and is therefore unlikely to align with evidence 
published in RCTs. Others have successfully argued that a 
lack of evidence does not mean a lack of efficacy and have 
used published case reports or phase II studies to support 
an application.
Clinicians and commissioners should be aware that the 
NHS has a duty to fund and resource medicines and treat-
ments recommended by NICE’s technology appraisals. 
Patients have the right to drugs and treatments that have been 
recommended by NICE for use in the NHS if their doctor 
believes they are clinically appropriate [89]. Although this 
may not currently be the case in certain CCGs, the authors 
emphasise that ongoing communication can optimise devel-
opment of sufficiently flexible pathways that can account for 
a variety of patient situations and minimise the need for a 
physician to challenge them.
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4  Discussion
The panel has discussed clinical freedom and clinical judge-
ment, which are two related concepts in the context of bio-
logics prescribing in England. Although both play a part in 
treatment decisions, clinical judgement is broader and goes 
beyond just treatment selection, considering situational fac-
tors such as those imposed by the healthcare system. The 
consensus reached shows that it is vital for physicians to 
be able to make clinical choices to best serve the variety of 
patients that they treat.
NHS working groups have already set out the importance 
of a collaborative approach in the commissioning of bio-
logics, including biosimilars, and offered some guidance 
as to how this could be achieved in the current climate of 
cost pressures and evidence gaps [11, 90]. We endeavour to 
enhance these processes by defining important concepts of 
clinical freedom, clinical judgement and drug value in the 
context of biologic prescribing.
In a variety of therapy areas, clinical guidance or deci-
sion-making tools have been shown to correlate with expert 
clinical judgement and to improve patient outcomes [39, 
91–94]. It has been demonstrated that improvements in 
available clinical tools and better knowledge thereof can 
alter clinical judgement [88]. Guidelines must therefore 
help to define treatment standards while accurately reflect-
ing areas of uncertainty to avoid limiting innovative prac-
tices in clinical care [72]. Treatment guidelines increasingly 
advocate that patient preference should factor into treatment 
decisions, thus permitting practice of personalised medicine 
to optimise patient adherence and treatment outcomes [1, 
9, 10, 34, 36, 37, 95, 96]. Furthermore, there will always 
be patients who fall outside of the available evidence and 
require expert interpretation for their treatment. For this 
reason, our proposals are intended to help re-align clinical 
judgement and commissioning decisions and to include the 
patient, who is directly impacted, in these discussions.
The debate on how best to balance competing demands 
when prescribing within a finite budget is ongoing. The 
quality-adjusted life-year (QALY) measure accounts for life 
length and quality and was designed to standardise health-
care funding decisions across diseases based on the degree 
of a treatment’s health benefit [45, 97–99]. The QALY is a 
cornerstone of NICE health technology appraisals and is 
seen as an important tool for ensuring maximum benefits 
when healthcare budgets are limited [97]. However, the 
QALY also remains problematic for applying a uni-dimen-
sional measure to the multi-dimensional nature of health 
effects without recognising non-health benefits [45, 97–99]. 
Is drug in the CCG 
pathway?
Absence from pathway/ 
CCG refusal
Review relevant NICE TA and guidelines
Is refusal in line with 
specific NICE TA/guidelines?




Consult with neighbouring and non-local physicians to 
gain multiple viewpoints on situation
















Local IFR process and guidance
Available evidence to support case, e.g. patient 
photos, patient statements, record of clinical 
outcome measures; consider patient associations
Psoriasis Association (www.psoriasis-
association.org.uk)
National Rheumatoid Arthritis Society 
(www.nras.org.uk)
(www.crohnsandcolitis.org.uk)
NICE psoriasis guidance: TA 521, 596, 575, 511, 
350, 537, 146, 180, 103, 134
BAD guidelines
NICE PsA guidance: TA 199, 220, 445, 537, 340
BSR guidelines
NICE CD guidance: TA 456, 352










Fig. 1  Process and resources for reaching a solution in the event of 
misalignment between clinical judgement as per NICE guidelines and 
a CCG pathway. BAD British Association of Dermatologists, BSG 
British Society of Gastroenterologists, BSR British Society for Rheu-
matology, CCG Clinical Commissioning Group, CD Crohn’s disease, 
IFR individual/independent funding request, NICE National Institute 
for Health and Care Excellence, TA treatment appraisal, UC ulcera-
tive colitis
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There are limitations to assessing a treatment based on the 
QALY, including false limitation of clinical freedom and 
potential hindrance of patient outcomes. Such limitations 
are likely to be exacerbated by personalised medicine [99]. 
Particularly pertinent to our recommendations are the ethical 
issues, wherein the QALY is unable to discriminate between 
individual patients or situational factors that may have a con-
siderable impact on the patient [97, 99]. In the UK, QALYs 
are usually based on general quality-of-life instruments that 
are not sufficiently sensitive to account for small but mean-
ingful health status changes in specific patient subgroups or 
the disease-specific experience [97, 99]. Examples include 
the individual with RA unable to type because of hand pain 
and stiffness, someone whose mobility and hand function are 
limited by palmoplantar psoriasis, or the person living with 
Crohn’s disease who misses appointments because of the 
need to remain close to a toilet, thus escaping incorporation 
into health technology assessments.
Our consensus recommendations align with the views of 
other groups: there can be advantages to incorporating addi-
tional attributes of benefit into analytical frameworks to sup-
port explicit and transparent decision making [45]. Yet, whilst 
there is a need for empirical assessment to support funding 
decisions and establish appropriate overall expenditure [45], 
the evidence is usually based on efficacy from strict RCT 
populations. For the majority of patients, access to medicines 
falls within QALY remits and calculations; it is for those who 
sit outside the norm, and who might typically be the subject 
of an IFR, that readjustment and harmonisation of services 
across England can be improved. Here, value frameworks 
could assist with value judgements and support transparency 
around prescribing decisions. An expanded-value framework 
has been proposed, incorporating a wider range of elements 
beyond the core of health gain and offset of cost savings, 
including productivity, reduction in uncertainty of response to 
treatment and value of hope [98]. In line with our own recom-
mendations and commentary from patient groups, the impor-
tance of including patients in discussions around value has 
also been highlighted [100]. This would be further enhanced 
by additional data for both health- and non-health benefits, 
spanning more complex, real-world cohorts as well as strin-
gent RCT populations. Such elements may not be the most 
important in definition of value, or the easiest to incorporate, 
and the relevant data may not yet exist [98, 99]. Yet, without 
consideration of these elements, patients may be subjected 
to inappropriate access decisions and the potential exists for 
suboptimal spending on healthcare [98, 99].
By way of enhancing the current situation, we have sup-
plemented the consensus on clinical freedom and biolog-
ics prescribing in England by suggesting practical ways 
to improve communication between clinicians and com-
missioners. We have attempted to enhance the existing 
decision-making processes by offering recommendations 
for collaboration, communication and resource sharing to 
facilitate solutions for patients with IMIDs, while consider-
ing the economic sustainability of the healthcare system. 
Finally, input from three relevant expert patient organisa-
tions indicates the applicability of these recommendations 
to the patients who are ultimately affected by any decisions 
(Box 2). As a future step, it would be valuable to gain per-
spective from commissioners from multiple CCGs and spe-
cialties to further understand the processes and relative dif-
ferences in commissioning decisions across England.
Box 2  Real-life applicability of these recommendations for patients—
statement from the National Rheumatoid Arthritis Society, Crohn’s & 
Colitis UK, and the Psoriasis Association
We welcome the exploration that value does not equal cost and echo 
the view that drug efficacy is important when considering drug 
value. Concordance is linked with efficacy, and the poorest-value 
drug is the one that is prescribed but not used.
We appreciate that clinical guidelines increasingly acknowledge the 
additional value of novel biologics with different modes of action. 
However, the guidelines are not being filtered down into practice. 
When decisions reach a local level, it too often comes back to 
cost. Better understanding of biologics and therefore personalised 
medicine has come a long way; however, this is being greatly 
stifled by the need for prescribing the cheapest biologic and not 
always following NICE guidance but instead CCG pathways. We 
would therefore agree with the authors that there is an inequitable 
postcode lottery in terms of biologic availability to patients.
As the patient is directly impacted, it is vital to include them in 
discussions at all stages of the care pathway. There should be an 
emphasis on shared decision making throughout, which requires 
the clinician to practice clinical freedom by aligning the patient’s 
needs and preferences with the available treatment choices. Yet, 
although shared decision making is listed in many principles of 
care, it often ends up as just rhetoric. It should involve a meaning-
ful discussion between physician and patient, reflective of the 
patient’s educational level, preferences and their home and work 
situation, about the risks and benefits of treatment. This enables 
the physician and patient to reach a joint decision that will suit the 
patient as an individual in terms of their disease and their personal 
situation.
In discussions around commissioning and care pathways, the 
patient’s perspective is also of value. This could include picture 
and video evidence from patients and their carers or families 
in debates with commissioners, or inclusion of expert patient 
organisations on decision boards. Patient organisations can help 
to provide context for commissioning decisions by recruiting 
patients with different characteristics for focus groups, highlight-
ing the importance of health outcomes and patient satisfaction as 
clear goals in clinical pathways.
4.1  Strengths and Limitations of These 
Recommendations
A Delphi process is affected by the number and representa-
tiveness of its participants, which will affect the range of 
discussion and quantity of data [41]. The project’s main 
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limitation is the small number of participants in the Delphi 
process. No guideline on the standard number of partici-
pants or the criteria against which an appropriate number of 
participants could be judged yet exist [101, 102]. Although 
Delphi panels most frequently consist of 10–100 partici-
pants [101, 102], it has been suggested that confidence in 
the results could still be maintained with a smaller Delphi 
panel if participants had similar training, knowledge and 
understanding of the field [101]. Our panellists were all from 
academic centres; the drugs discussed here are typically pre-
scribed in secondary care, so physicians in academic centres 
are likely to have the greatest experience and understanding 
of their use, benefits and drawbacks in patients with complex 
needs. As a future step, there could be value in expanding 
the consensus statements defined and voted upon here to a 
wider group of physicians, to understand the applicability to 
the general population of biologic-eligible patients.
A key strength of this project is its cross-specialty focus. 
Inclusion of both specialist physicians and feedback from 
multiple patient groups highlight the broad scope of the 
issues discussed. Each panellist represented a different 
CCG; although some may be geographically close, such as 
those in London, there are discrepancies even within neigh-
bouring boroughs of the capital, which further highlight the 
issue under discussion. The commentary from patients in 
particular indicates the relevance of these issues to those 
ultimately affected. Given the interlinked nature of many 
IMIDs, in both their manifestation and their management, 
these practical recommendations have the potential to benefit 
a greater number of patients than if they were to address just 
one disease.
5  Conclusions
This consensus highlights that clinicians must be able to 
exercise clinical freedom in order to best serve patients; 
however, this is necessarily limited by the funding restric-
tions of a healthcare system. Striking a balance between 
clinical freedom and short-term cost restrictions is vital 
to support equitable resource distribution. Consideration 
of these recommendations may help to harmonise local, 
regional and national services through a multi-stakeholder 
approach involving policy and patient groups as well as 
physicians and commissioners, improve data generation to 
support value-based prescribing decisions, and ultimately 
ensure equity of patient access to biologic treatments.
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